CA3228845A1 - Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction - Google Patents

Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction

Info

Publication number
CA3228845A1
CA3228845A1 CA3228845A CA3228845A CA3228845A1 CA 3228845 A1 CA3228845 A1 CA 3228845A1 CA 3228845 A CA3228845 A CA 3228845A CA 3228845 A CA3228845 A CA 3228845A CA 3228845 A1 CA3228845 A1 CA 3228845A1
Authority
CA
Canada
Prior art keywords
bag3
polynucleotide
polypeptide
vector
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228845A
Other languages
English (en)
French (fr)
Inventor
Arthur M. Feldman
Douglas G. Tilley
Weizhong Zhu
Kamel Khalili
Walter J. Koch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3228845(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of CA3228845A1 publication Critical patent/CA3228845A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
CA3228845A 2014-01-31 2015-01-30 Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction Pending CA3228845A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934483P 2014-01-31 2014-01-31
US61/934,483 2014-01-31
CA2975258A CA2975258A1 (en) 2014-01-31 2015-01-30 Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2975258A Division CA2975258A1 (en) 2014-01-31 2015-01-30 Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction

Publications (1)

Publication Number Publication Date
CA3228845A1 true CA3228845A1 (en) 2015-08-06

Family

ID=53757927

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3228845A Pending CA3228845A1 (en) 2014-01-31 2015-01-30 Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
CA2975258A Pending CA2975258A1 (en) 2014-01-31 2015-01-30 Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2975258A Pending CA2975258A1 (en) 2014-01-31 2015-01-30 Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction

Country Status (10)

Country Link
US (3) US11236389B2 (OSRAM)
EP (2) EP3099333B8 (OSRAM)
JP (4) JP6920818B2 (OSRAM)
CA (2) CA3228845A1 (OSRAM)
DK (1) DK3099333T3 (OSRAM)
ES (1) ES2838804T3 (OSRAM)
HU (1) HUE052814T2 (OSRAM)
PT (1) PT3099333T (OSRAM)
SI (1) SI3099333T1 (OSRAM)
WO (1) WO2015117010A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3228845A1 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
WO2017031182A2 (en) 2015-08-17 2017-02-23 Temple University Of The Commonwealth System Of Higher Education Bag3 compositions and methods
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
KR101804678B1 (ko) 2016-05-30 2017-12-04 가톨릭대학교 산학협력단 Bis 억제제 스크리닝용 마커, 이를 포함하는 스크리닝 키트 및 이를 이용한 bis 억제제 스크리닝 방법
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
WO2018031738A2 (en) * 2016-08-11 2018-02-15 Temple University Of The Commonwealth System Of Higher Education Ischemia/reperfusion injury
US20190328836A1 (en) * 2017-01-09 2019-10-31 Duke University Methods for treating ischemic injury
IT201700113648A1 (it) * 2017-10-10 2019-04-10 Biouniversa Srl Anti-BAG3 antibodies as therapeutic reagent in cardiovascular diseases
EP3658582A1 (en) 2017-07-28 2020-06-03 Intrepida Bio, Inc. Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
WO2019158619A1 (en) * 2018-02-15 2019-08-22 Bjoerklund Tomas Modified viral capsids
WO2019237002A1 (en) * 2018-06-08 2019-12-12 Temple University - Of The Commonwealth System Of Higher Education Optimizing bag3 gene therapy
WO2020097525A1 (en) 2018-11-08 2020-05-14 University Of Miami Method of determining responsiveness to cell therapy in dilated cardiomyopathy
US20220088127A1 (en) * 2019-01-15 2022-03-24 Temple University - Of The Commonwealth System Of Higher Education Targeting the bag family for the treatment of neurodegenerative disease
WO2020205889A1 (en) 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
KR20240063110A (ko) * 2021-08-12 2024-05-10 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치료제의 역행성 관상 정맥 또는 정맥동 투여
IL312509A (en) * 2021-10-22 2024-07-01 Univ Loyola Chicago BAG3 methods and uses for treating inflammation
CA3242351A1 (en) * 2021-12-10 2023-06-15 University Of Florida Research Foundation, Incorporated Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
WO2023147558A2 (en) * 2022-01-28 2023-08-03 Temple University - Of The Commonwealth System Of Higher Education Crispr methods for correcting bag3 gene mutations in vivo
EP4511048A2 (en) * 2022-04-22 2025-02-26 Spacecraft Seven, LLC B-cell lymphoma 2-associated anthanogene 3 (bag3) gene therapy using aav vector
IL316559A (en) * 2022-05-03 2024-12-01 Univ Temple Quality control of BAG3 and brain proteins
AU2023342101A1 (en) * 2022-09-16 2025-04-10 Temple University Of The Commonwealth System Of Higher Education Bag 3 methods and uses for treatment of cardiac amyloidosis

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US4907603A (en) 1988-01-04 1990-03-13 Bertha D. Chambers Safety smoke
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5670113A (en) 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CA2178729A1 (en) 1993-12-09 1995-06-15 Eric B. Kmiec Compounds and methods for site-directed mutations in eukaryotic cells
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
ATE317916T1 (de) 2001-11-13 2006-03-15 Univ Pennsylvania Verfahren zur identifizierung von adeno- assoziiertem virus (aav) sequenzen sowie kit zur ausführung der methode
EP1323733A1 (en) 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
US20030175958A1 (en) * 2002-03-15 2003-09-18 Reed John C. Methods for using bag expression as a cell differentiation agent and marker
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
WO2012087835A2 (en) * 2010-12-22 2012-06-28 Boston Biomedical Research Institute Compositions and methods for enhancing protein folding
WO2012107580A1 (en) 2011-02-10 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) In vitro diagnosis method for predicting a predisposition to cardiomyopathy
CA3228845A1 (en) 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
KR20240063110A (ko) 2021-08-12 2024-05-10 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치료제의 역행성 관상 정맥 또는 정맥동 투여

Also Published As

Publication number Publication date
JP2024175055A (ja) 2024-12-17
EP3099333B1 (en) 2020-11-18
US20230073246A1 (en) 2023-03-09
EP3099333B8 (en) 2020-12-30
EP3099333A2 (en) 2016-12-07
WO2015117010A3 (en) 2015-09-24
HUE052814T2 (hu) 2021-05-28
US20170016066A1 (en) 2017-01-19
JP7079761B2 (ja) 2022-06-02
JP7558218B2 (ja) 2024-09-30
EP3099333A4 (en) 2017-09-06
ES2838804T3 (es) 2021-07-02
SI3099333T1 (sl) 2021-04-30
PT3099333T (pt) 2020-12-24
US11236389B2 (en) 2022-02-01
JP2020079235A (ja) 2020-05-28
CA2975258A1 (en) 2015-08-06
JP2022116125A (ja) 2022-08-09
JP2017506623A (ja) 2017-03-09
US20210017600A1 (en) 2021-01-21
US11542555B2 (en) 2023-01-03
JP6920818B2 (ja) 2021-08-18
DK3099333T3 (da) 2021-02-01
EP3812473A1 (en) 2021-04-28
WO2015117010A2 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
US20230073246A1 (en) Bag3 as a target for therapy of heart failure
Sheen et al. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome
Carmignac et al. C‐terminal titin deletions cause a novel early‐onset myopathy with fatal cardiomyopathy
Bevan et al. Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery
Yoshimura et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype
Qiao et al. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery
US20130210663A1 (en) Methods and compounds for the diagnosis and treatment of cancer
WO2004092384A2 (en) Means and methods for diagnosing and treating affective disorders
Salah et al. MCP-1 promotes detrimental cardiac physiology, pulmonary edema, and death in the cpk model of polycystic kidney disease
JP7614844B2 (ja) Ｂａｇ３遺伝子治療の最適化
Guo et al. A novel splice mutation induces exon skipping of the EXT1 gene in patients with hereditary multiple exostoses
Rutschow et al. S151A δ-sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice
JP7565264B2 (ja) リンパ系疾患の診断および治療のための組成物および方法
HK40051293A (en) Bag3 as target for therapy of heart failure
RU2842423C2 (ru) Оптимизация генотерапии bag3
US11235029B2 (en) Methods for treating heart failure with a TRKB agonist
Lornage Identification and functional characterization of novel genes implicated in congenital myopathies
WO2014095916A1 (en) Ninjurin-1 as therapeutic target for brain tumor
Ringhoff Stathmin regulation of interphase cells: Implications for cancer research
JP2006109732A (ja) 糖代謝調節剤、およびそのスクリーニング方法
CA2836032A1 (en) Diagnostic test and treatment for a neurological disorder

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240205

EEER Examination request

Effective date: 20240205

EEER Examination request

Effective date: 20240205

EEER Examination request

Effective date: 20240205